Clinical trial
A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia
NCT01227278 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- July 31, 2013
- Enrollment
- 421 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.